Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. 

The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, haematology, ophthalmology, and other diseases. 

Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

The headquarters and the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, and the factory in Takada was rebuilt. In 1969,  The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.

In March 2015 the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.

“Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world.”

“We will be a top innovator in the healthcare industry, achieving patient-centred, high-level, sustainable medical care, based on our unique science and technology capabilities.”